Xcout Intel
HemostOD competitors & alternatives
The 12 closest competitors and alternatives to HemostOD among healthcare biotech companies — ranked by similarity to what HemostOD actually does, not by market-cap band.
Subscribe to see HemostOD’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About HemostOD
HemostOD is a preclinical-stage biotech company based in Lausanne, Switzerland, pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets to save lives.
HemostOD at a glance
HemostOD is a healthcare biotech company headquartered in Switzerland. It has raised at least $6.5M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $4.7M in October 2025. Xcout tracks 5 named people at HemostOD, including Faouzi Khechana (CEO).
HemostOD leadership
- Faouzi KhechanaCEO
- Elodie DahanCTO
- Laurent MassuyeauExecutive Chairman
- Nicoletta SorvilloCSO
- Thierry NiclouxHead of Operations
HemostOD funding rounds
At least $6.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $4.7M | — | |
| Seed | $1.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 HemostOD competitors
Ranked by semantic similarity — how close each company is to HemostOD by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Cayuga Biotech is a biotechnology company developing novel therapies to address life-threatening hemorrhage by harnessing the body's innate ability to stop bleeding.
Biotechnology
Hemoglobin Oxygen Therapeutics LLC develops oxygen-carrying solutions, such as its Hemopure product, for medical applications including organ transplants and preservation. The company serves the healthcare and medical research sectors by providing hemoglobin-based therapeutics used in clinical studies and surgical procedures.
Biotechnology
Ferrosa Therapeutics AG is a Swiss biotechnology company founded in Basel, Switzerland, focusing on developing novel therapeutics to treat anemia and related conditions.
Biotechnology
Bioxodes is a Belgian clinical-stage biotechnology company founded in 2013 and located in Gosselies. The firm focuses on developing breakthrough treatments for hemorrhagic stroke patients.
Biotech
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
Biotech
ATLyphe is a Swiss biotechnology spin-off from ETH Zurich and the University of Zurich founded in 2023 and based in Zürich. The company develops antibody-based solutions engaging T cells for precision immunotherapy, with a focus on improving hematopoietic stem cell transplantation conditioning methods.
Biotech
TreeFrog Therapeutics is a French-based biotech company headquartered in Pessac, France. It aims to make iPS-derived cell therapies safer, more efficient, and more affordable to cure millions of patients.
Biotech
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Biotech
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Biotech
Abologix Sàrl is a biopharma and manufacturing company founded in 2018 and headquartered in Plan-les-Ouates, Geneva, Switzerland. It operates within the life sciences and antibodies sector.
Biotech
TECregen AG is a biotechnology company headquartered in Basel, Switzerland. The company is dedicated to advancing immuno-rejuvenation through the development of next-generation therapies designed to regenerate the thymus.
Biotechnology
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of HemostOD and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for HemostODand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →